World Gastroenterology Organisation Global Guidelines: Diagnosis, Management and Prevention of Hepatitis C April 2013

Journal of Clinical Gastroenterology

Volumn 48, Issue 3, 2014, Pages 204-217

  Umar, Muhammed ^a   Khan, Aamir G ^a   Abbas, Zaigham ^a   Arora, Sanjeev ^a   Asifabbas, Naqvi ^a   Elewaut, Andre ^a   Esmat, Gamal ^a   Foster, Graham ^a   Fried, Michael ^a   Goh, Khean L ^a   Hamama, Tul Bushra Khaar ^a   Imawari, Michio ^a   Isakov, Vasily ^a   Krabshuis, Justus ^a   Labrecque, Douglas ^a   Lemair, Anton ^a   Malfertheiner, Peter ^a   Ryder, Steve ^a   Schiedermaier, Peter ^a   Stimac, Davor ^a   Tandon, Rakesh ^a   Villamil, Federico ^a   Zapata, Rodrigo ^a   Ferenci, Peter ^a   more..

^a HOLY FAMILY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84894220916     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000050     Document Type: Review

References (32)

1. Mandeville KL, Krabshuis J, Ladep NB, et al. Gastroenterology in developing countries: Issues and advances. World J Gastroenterol. 2009;15:2839-2854.
2. Zou S, Tepper M, EI Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol. 2000;14:575-580.
3. Palitzsch KD, Hottentrager B, Schlottmann K, et al. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol. 1999;11:1215-1220.
4. Umar M, Khaar HB, Khan AA, et al. Diagnosis, management and prevention of hepatitis C in Pakistan 2009. Pak J Gastroenterol. 2009;23:7-67.
5. Qureshi H. Prevalence of Hepatitis B & C in Pakistan. Islamabad, Pakistan: Pakistan Medical Research Council; 2008.
6. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of HCV in Egypt. Lancet. 2000;355:887-891.
7. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52.
8. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809-816.
9. Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol. 2006;4:1271-1277.
10. Jacobson IM, Davis GL, El-Serag H, et al. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8:924-933.
11. Beinhardt S, Aberle JH, Strasser M, et al. Serum level of IP-10 improves predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012;142:78-85.
12. Vogt M, Lang T, Frösner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341: 866-870.
13. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(suppl 1):S34-S38.
14. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(SUPPL1):S30-S34.
15. Fried MW, ShiffmanML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
16. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
17. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: Efficacy, side effects, and complications. Gut. 2006;55:1350-1359.
18. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
19. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-965.
20. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.
21. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
22. Hamid S, Umar M, Alam A, et al. PSG consensus statement on management of hepatitis C virus infection-2003. J Pak Med Assoc. 2004;54:146-150, Available at: Http://www. psg.org.pk/new/PSGHCV.pdf. Accessed July 25, 2013.
23. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
24. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.
25. Martínez SM, Crespo G, Navasa M, et al. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325-335.
26. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444, Available at: Http://www.aasld.org/practiceguidelines/Docu ments/2011UpdateGenotype1HCVbyAASLD24641.pdf. Accessed July 25, 2013.
27. Omata M, Kanda T, Yu ML. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6:409-436, Available at: Http://www.chinese fms.com/doc/zhw/zxdt/201203/ P020120321562034553835.pdf. Accessed July 25, 2013.
28. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: One pill a day for tomorrow. Liver Int. 2012;32(SUPPL1):88-102.
29. Beinhardt S, Staettermayer AF, Rutter K, et al. Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: Is there a selection bias? Hepatology. 2012;55:30-38.
30. Myers RP, Ramji A, Bilodeau M, et al. An update on the management of hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol. 2012;26:359-375.
31. Hussain AB, Hussain T, Anwar M, et al. Treatment response in HCV related chronic hepatitis. J Coll Physicians Surg Pak. 2004;14:466-469.
32. Qureshi S, Batool U, Iqbal M, et al. Response rates to standard interferon treatment in HCV genotype 3a. J Ayub Med Coll Abbottabad. 2009;21:10-14.